

Victor Vogel, MD

Books and Chapters

1. Civin CI, **Vogel VG**, Strauss LC. Tumor markers in adolescent oncology. In: Tebbi C, Ed. *Major Topics in Adolescent Oncology*, Futura Medical Publishers, New York, 1987, 351-409.
2. Winn RJ, Coody D, **Vogel VG**, Spitz M, Newell G. The management of familial colon cancer in a special risk clinic. In: Levin B, Ed. *Gastrointestinal Cancer: Current Approaches to Diagnosis and Treatment*. Annual Clinical Conference on Cancer. Vol 30, University of Texas Press, Austin, 1988, 15315-8.
3. **Vogel VG**, Love RR. High-risk group and cost strategies. In: Stoll B, Ed. *Approaches to Breast Cancer Prevention*. Kluwer, Dordrecht, 1991, 207-220.
4. Macheledt JE, **Vogel VG**. The epidemiology of cancer. In: Pazdur R, Ed. *Medical Oncology: A Comprehensive Review*. PRR, Inc., Huntington, NY, 1993, 503-510.
5. **Vogel VG**. *Counseling the high-risk woman*. In: Stoll BA, Ed. *Reducing Breast Cancer Risk in Women*. Kluwer Academic Publishers, Dordrecht 1995, 69-80.
6. **Vogel VG**. Tamoxifen for the prevention of breast cancer. In: DeVita VT Jr., Hellman S, Rosenberg SA, Eds. *Important Advances in Oncology - 1995*. J.B. Lippincott, Philadelphia 187-200.
7. Nazario LA, Macheledt JE, **Vogel VG**. Epidemiology of cancer and prevention strategies. In: Pazdur R, Ed. *Medical Oncology - A Comprehensive Review*, PRR Inc., New York, 1995, 661-671.
8. **Vogel VG**. Prevention of breast cancer - clinical considerations. In: Harris J, Hellman S, Lippman M, Morrow M, Eds. *Diseases of the Breast*. J.B. Lippincott, Philadelphia 1996, 341-354.
9. **Vogel VG**. Breast cancer risk factors and preventive approaches to breast cancer. In Kavanagh J, Singletary SE, Einhorn N, DePetrillo AD, Eds. *Cancer in Women*, Blackwell Scientific Publications, Inc., Cambridge, MA, 1998; 58-91.
10. **Vogel VG**. Primary prevention of breast cancer. In: Bland KI, Copeland EM, Eds. *The Breast: Comprehensive Management of Benign and Malignant Disease*, 2nd edition, Volume 1, W.B. Saunders Co., Philadelphia, 1998; 18:352-369.
11. **Vogel VG**. Prevention of breast cancer. In: Singletary SE, Robb G, Eds. *Advanced Therapy of Breast Disease*. B.C. Decker, Inc., St. Louis, 2000, 27-35.
12. **Vogel VG** (Editor). *Breast Cancer Prevention CM Monographs*. Discovery International, Deerfield, Ill., 2000.
13. **Vogel VG** (Editor). *Management of Patients at High Risk for Breast Cancer*. Blackwell Science Inc. Malden, MA, 2001.
14. **Vogel VG**. Chemoprevention: reducing breast cancer risk, in **Vogel VG** (Editor). *Management of Patients at High Risk for Breast Cancer*. Blackwell Science Inc. Malden, MA, 2001, 201-227.

15. Laman A, **Vogel VG**. Primary prevention of breast cancer. In: Bland KI, Copeland EM, Eds. *The Breast: Comprehensive Management of Benign and Malignant Disease*, 3rd edition, Volume 1, W.B. Saunders Co., Philadelphia, 2004, 355-373.
16. **Vogel VG**. Epidemiology of breast cancer. In: Bland KI, Copeland EM, Eds. *The Breast: Comprehensive Management of Benign and Malignant Disease*, 3rd edition, Volume 1, W.B. Saunders Co., Philadelphia, 2004, 341-354.
17. **Vogel VG**, and Bevers T, Editors. *Handbook of breast cancer risk assessment: Evidence-based guidelines for evaluation, prevention, counseling, and management*. Jones and Bartlett Publishers, Boston, 2003
18. **Vogel VG**. Epidemiology of breast cancer, In: **Vogel VG**, and Bevers T, Editors. *Handbook of breast cancer risk assessment: Evidence-based guidelines for evaluation, prevention, counseling, and management*. Jones and Bartlett Publishers, Sudbury, Mass. 2003, pages 1-9.
19. Gierach G, **Vogel V**. "Epidemiology of breast cancer" In: Singletary SE, Robb GL, Hortobagyi GN (Editors). *Advanced Therapy of Breast Disease (Second Edition)*. B. C. Decker, Inc., Hamilton, Ontario, 2004, pages 58-83
20. Rastogi P, Lo S, **Vogel VG**. Chemoprevention: clinical aspects. In: Harris J, Lippman M, Morrow M, Osborne CK, Eds. *Diseases of the Breast*, 3rd edition. J.B. Lippincott, Philadelphia, 2004, 363-380.
21. **Vogel VG**. "Breast Disorders" in *The Merck Manual*, 18th Edition, 2005, 2108-2118.
22. **Vogel VG**. "Epidemiology of breast cancer," In: Winchester DJ, Winchester DP, Hudis CA, Norton L (Editors). *Breast Cancer*, Second Edition, BC Decker, Inc., 2006, 47-60.
23. Reeder J, **Vogel VG**. "Breast Cancer Prevention," in *Advances in Breast Cancer Management*, 2nd Edition, Kluwer, Boston, MA (in press)

Victor Vogel, MD

Publications 2004-2006

Peer Reviewed

1. Thull D, **Vogel VG**. Recognition and management of hereditary breast cancer syndromes. *The Oncologist* 2004; 9:13-24.
2. Hollingsworth AB, Singletary SE, Morrow M, Francescatti DS, O'Shaughnessy JA, Hartman A-R, Haddad B, Schnabel FR, **Vogel VG**. Current comprehensive assessment and management of women at increased risk for breast cancer. *American Journal of Surgery* 2004; 187:349-362.
3. Xiao D, Johnson DE, **Vogel V**, and Singh SV. Diallyl Trisulfide Induced Cell Death in Human Prostate Cancer Cells Involves Proteasomal Degradation and c-Jun N-Terminal Kinase 1 Mediated Phosphorylation of Bcl-2. *Oncogene* 23:5594-606, 2004
4. **Vogel V**. In the dark in the ADIZ. *AOPA Pilot* 48 (6):168-171, 2005.

5. Latimer JJ, Rubinstein WS, Johnson JM, Kanbour-Shakir A, **Vogel VG**, Grant SG. Haploinsufficiency for *BRCA1* is associated with normal levels of DNA nucleotide excision repair in breast tissue and blood lymphocytes. *Biomed Central Medical Genetics* 2005, 6:26.
6. Romond EH, Perez EA, Bryant J, Suman V, Geyer CE, Jr., Davidson N, Tan-Chiu E, Martino S, Paik S, Kaufman P, Swain SM, Pisansky T, Fehrenbacher L, Kutteh LA, **Vogel V**, Visscher D, Yothers G, Jenkins R, Brown AM, Dakhil SR, Mamounas T, Lingle W, Abrams J, Ingle JN, Wolmark N. Adjuvant Chemotherapy with or without Trastuzumab for HER2-Positive Breast Cancer: Combined Analysis of NSABP B-31 and NCCTG N9831. *New England Journal of Medicine* 2005; 353:1659-1672.
7. Tan-Chiu E, Yothers G, Romond E, Geyer CE Jr., Ewer M, Keefe D, Shannon R, Swain S, Brown A, Fehrenbacher L, **Vogel V**, Seay TE, Rastogi P, Mamounas E, Wolmark N, and Bryant J. Assessment of cardiac dysfunction in a randomized trial comparing Doxorubicin and Cyclophosphamide followed by Paclitaxel, with or without Trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. *Journal of Clinical Oncology* 2005;23:7811-7819.
8. Okobia MN, Bunker CH, Zmuda JM, **Vogel VG**, Uche EEO, Anyanwu SNC, Ezeome ER, Ferrell RE, Kuller LH. Cytochrome P4501A1 genetic polymorphisms and breast cancer risk in Nigerian women. *Breast Cancer Research and Treatment* 2005; 94:285-293.
9. Modugno F, Ngo DL, Allen GO, Kuller LH, Ness RB, **Vogel VG**, Costantino JP, Cauley JA. Breast cancer risk factors and mammographic density in women over age 70. *Breast Cancer Research and Treatment* 93(3):261-270, 2005.
10. Singh SV, Zeng Y, Xiao D, **Vogel VG**, Nelson JB, Dhir R, Tripathi YB. Caspase-dependent apoptosis induction by guggulsterone, a constituent of Ayurvedic medicinal plant *Commiphora mukul*, is mediated by Bax and Bak. *Molecular Cancer Therapeutics* 4:1747-1754, 2005 .
11. Atkins J, Jacobs SA, Wieand HS, Smith RE, John W, Colangelo L, **Vogel V**, Kuebler P, Cescon TP, Miller B, Geyer CE, Jr., Wolmark N. Pemetrexed and Oxaliplatin for First-Line Treatment of Patients with Advanced Colorectal Cancer: A Phase II Trial of the NSABP Foundation Research Program. *Clinical Colorectal Cancer* 5(3):181-187, 2005.
12. **Bender** CM, Sereika SM, Berga SL, **Vogel VG**, Brufsky AM, Paraska KK, Ryan CM. Cognitive impairment associated with adjuvant therapy in breast cancer. *Psycho-Oncology* 15(5):422-30, 2006.
13. Beattie MS, Costantino JP, Cummings SR, Wickerham DL, Wolmark N, Dowsett M, Folkerd EJ, Willett WC, **Vogel VG**, Hankinson SE. Endogenous Sex Hormones, Risk of Breast Cancer, and Response to Tamoxifen: An Ancillary Study in the NSABP Breast Cancer Prevention Trial (P-1). *Journal of the National Cancer Institute* 98:110-115, 2006.
14. **Vogel VG**, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Jr., Wade JL, III, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, MD, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N. Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes: The NSABP Study of Tamoxifen

and Raloxifene (STAR) P-2 Trial. *Journal of the American Medical Association* 295(23):2727-2741, 2006.

15. Land SR, Wickerham DL, Costantino JP, Ritter MW, **Vogel VG**, Lee M, Pajon ER, Wade JL, Dakhil S, Lockhart JB, Wolmark N, Ganz PA. Patient-Reported Symptoms and Quality of Life During Treatment with Tamoxifen or Raloxifene for Breast Cancer Prevention: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. *Journal of the American Medical Association* 295(23):2742-2751, 2006.
16. Rubinstein WS, Latimer JJ, Sumkin JH, Huerbin M, Grant SG, **Vogel VG**. Prospective screening study of 0.5 Tesla dedicated magnetic resonance imaging for the detection of breast cancer in young, high-risk women. *BMC Women's Health*, 6:10, 2006.
17. O'Neill SM, Peters JA, Vogel VG, Feingold E, Rubinstein WS. Referral to cancer genetic counseling: Are there stages of readiness? *Am J Med Genet Part C Semin Med Genet* 142C:221-231, 2006.
18. Khatcheressian JL, Wolff AC, Smith TJ, Grunfeld E, Muss HB, **Vogel VG III**, Somerfield MR, Davidson NE for the American Society of Clinical Oncology Breast Cancer Surveillance Expert Panel. American Society of Clinical Oncology 2005 Update of Recommended Breast Cancer Surveillance Guidelines. *Journal of Clinical Oncology* 24:5091-5097, 2006
19. **Vogel VG**. Identifying and screening patients at risk of second cancers. *Cancer Epidemiol Biomarkers Prev* 15:2027-2032, 2006
20. Latimer JJ, Stolz DB, Guiliano K, Kelly CM, Johnson JM, Focht D, Amortegui A, Grant SG and **Vogel VG**. Long-lived primary human mammary epithelial cultures reiterate organotypic structures. *Nature Methods* (in press)
21. Soran A, D'Angelo G, Ardic F, Begovic M, Harlak A, Wieand HS, **Vogel VG**, Johnson RR. Breast cancer related lymphedema; what are the significant predictors and how do they affect the severity of lymphedema? *The Breast Journal* (in press)
22. Okobia MN, Bunker CH, Zmuda JM, Kammerer CM, **Vogel VG**, Uche EEO, Anyanwu SNC, Ezeome ER, Kuller LH, Ferrell RE. Case-control study of risk factors for breast cancer in Nigerian women. *International Journal of Cancer* (in press)
23. Davidson B, **Vogel V**, Wickerham DL. Oncologist-patient discussion of adjuvant hormonal therapy in breast cancer: results of a linguistic study focusing on adherence and persistence to therapy. *Journal of Supportive Oncology* (in press)
24. Singh S, et al. "Benzyl isothiocyanate-induced apoptosis in human breast cancer cells is initiated by reactive oxygen species and regulated by Bax and Bak. *Mol Cancer Therapeutics* (in press)
25. Latimer JJ, Giuliano K, Kelly CM, Johnson JM, Focht D, Amortegui A, Grant SG, **Vogel VG**, Stolz DB. A novel paradigm for mammary tissue engineering using embryonic stem cell based medium. *Nature Methods* (submitted)

26. Okobia MN, Bunker CH, Zmuda JM, **Vogel VG**, Uche EEO, Anyanwu SNC, Ezeome ER, Kuller LH, Ferrell RE. Association of catechol-O-methyl transferase (COMT) gene and breast cancer in Nigerian women Breast Cancer Research (submitted)
27. Greenspan SL, Bhattacharya RK, Sereika SM, **Vogel VG**. Prevention of bone loss in survivors of breast cancer. (submitted)
28. Simpson JK, Modugno F, Wiessfeld JL, Costantino J, **Vogel V**, Kuller LH, Bauer DC, Stone KL, Cauley JA. Determinants of estrogen metabolite levels in postmenopausal women. (submitted)
29. Simpson JK, Modugno F, Costantino J, **Vogel V**, Kuller L, Cauley JA, Weissfeld JL. Breast density and the relationship with 2-hydroxyestrone and 16 α -hydroxyestrone. (submitted)
30. Simpson JK, Modugno F, Wiessfeld JL, Costantino J, **Vogel V**, Kuller LH, Cauley JA. Breast density, 2-hydroxyestrone, 16 α -hydroxyestrone and the risk of breast cancer. (submitted)
31. Gierach GL, Modugno F, Cauley JA, Weissfeld JL, Wilson JW, Simpson JK, Allen GO, Salane M, Tracy RP, **Vogel VG**. Soluble tumor necrosis factor-alpha receptors I and II and mammographic density amount postmenopausal women: The mammograms and masses study (MAMS). (submitted)
32. Gierach GL, Modugno F, Cauley JA, Weissfeld JL, Wilson JW, Simpson JK, Allen GO, Romkes M, Salane M, **Vogel VG**. A polymorphism in the tumor necrosis factor-alpha receptor II gene, circulating soluble TNRR-II, and mammographic density: The mammograms and masses study (MAMS). (submitted)
33. Gierach GL, Modugno F, Weissfeld JL, Wilson JW, **Vogel VG**, Cummings SR, Tice J, Ziv E, Cauley JA. Nonsteroidal anti-inflammatory drug use and breast cancer in older women: The study of osteoporotic fractures. (submitted)

Invited

1. Lo Shelly, **Vogel VG**. Endocrine prevention of breast cancer using selective estrogen receptor modulators (SERMs). *Clinical Endocrinology and Metabolism* 18 (1):97-111, 2004
2. Rastogi P, **Vogel V**. Update on breast cancer prevention. *Oncology* 2003; 17:799-805.
3. Rastogi P, **Vogel V**. Overview of breast cancer chemoprevention trials. *Seminars in Breast Disease* 6 (1):1-10, 2003.
4. **Vogel V**. Ductal lavage in women at high risk for breast cancer. *Proceedings from the 5th International Multidisciplinary Congress 2003*, 171-174.
5. Runowicz CD, Dawson AE, Newman LA, **Vogel VG**. New perspectives on breast cancer risk assessment. *Contemporary OB/GYN (Suppl)* pages 4-20, June 2003.
6. **Vogel V**. Atypia in the assessment of breast cancer risk: implications for management. *Diagnostic Cytopathology* 30:151-157, 2004.

7. Hortobagyi GN, Goss PE, Gradishar WJ, Mortimer JE, **Vogel VG**. The Role of Anti-Aromatase Agents in New Treatment Strategies for Breast Cancer. American Academy of CME, Inc. April 2004, p 17-21.
8. Monga D, **Vogel VG**. The Wong/Ellis article reviewed. *Oncology* 2004; 18:429, 432.
9. Kapoor A, **Vogel VG**. Prognostic factors for breast cancer and their use in the clinical setting. *Expert Reviews in Anticancer Therapy* 5(2): 269-281, 2005.
10. **Vogel V**. Chemoprevention in breast cancer. *Clinical Advances in Hematology and Oncology* 3:531-533, 2005.
11. **Vogel VG**. Can statin therapy reduce the risk of breast cancer? (Editorial) *Journal of Clinical Oncology* 23:8553-8555, 2005.
12. Shapiro CL, Pulhalla S, Sokolowicz LE, Gradishar WJ, Calvo A, **Vogel VG**. Switching from tamoxifen to exemestane in localized breast cancer: four representative case studies. *Community Oncology*, April 2006; p 2- 8.
13. Rastogi P, **Vogel VG**. Update on breast cancer prevention. *Salud(i)Ciencia (SIIC)* 14 (6): 366-367, 2006.
14. **Vogel VG** and Taioli E. Have we found the ultimate risk factor for breast cancer? (Editorial) *Journal of Clinical Oncology* 24: 1791-1793, 2006.
15. **Vogel V**. Management of high risk for breast cancer: an overview. *Proceedings of the International Union Against Cancer (UICC) 2006, Bridging the Gap: Transforming Knowledge into Action*, Abstract # 207-3: 594-598, 2006.
16. **Vogel VG**. Understanding Breast Cancer Risk Assessment. *Effective Application of Breast Cancer Risk Assessment in Clinical Practice. Contemporary OB/GYN (Suppl)* pages 6-9, July 2006.
17. Geller BA, **Vogel VG**. Chemoprevention of breast cancer in postmenopausal women. *Breast Disease* 24:79-92, 2005-2006.
18. **Vogel VG**. Recent results from clinical trials using SERMs to reduce the risk of breast cancer. *Annals of the New York Academy of Science* 1089: 127-142, 2006
19. **Vogel VG**. Chemoprevention in Breast Cancer. *Cancer and Chemotherapy Reviews* 2:33-40, 2007.
20. **Vogel VG**. Chemoprevention Strategies 2006. *Current Treatment Options in Oncology* (in press)
21. **Vogel VG**. Raloxifene: a second-generation selective estrogen receptor modulator for reducing the risk of invasive breast cancer in postmenopausal women. *Future Drugs* (in press)